NASDAQ:IMCR Immunocore Q3 2026 Earnings Results & Report $29.68 +1.28 (+4.51%) As of 11:02 AM Eastern This is a fair market value price provided by Massive. Learn more. Immunocore missed analyst earnings expectations in its Q3 2026 results, released November 6, 2026. The company reported EPS of -$0.28 versus the -$0.1305 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 6, 2026TimeBefore Market OpensConference Call7:00 AM ET Immunocore EPS ResultsActual EPS-$0.28Consensus EPS -$0.1305Beat/MissMissed by -$0.1496One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersImmunocore Revenue ResultsActual RevenueN/AExpected Revenue$152.36 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Quarterly report(10-Q) Immunocore Q3 2026 Earnings FAQ Did Immunocore beat earnings estimates for Q3 2026? Immunocore (NASDAQ:IMCR) reported earnings of -$0.28 per share for Q3 2026, missing the consensus estimate of -$0.1305. The report was announced on Friday, November 6, 2026. Immunocore Earnings HeadlinesImmunocore reports third quarter financial results and provides a business update2 hours ago | globenewswire.comAnalysts Conflicted on These Healthcare Names: Solventum Corporation (SOLV), HCA Healthcare (HCA) and Immunocore Holdings (IMCR)October 30, 2026 | theglobeandmail.comThe best investor alive just called this market outWarren Buffett told CNBC's Becky Quick it's tough to find values when everybody is preferring gambling, a blunt line aimed at the broader market, not just meme stocks. Weiss Ratings runs 1.2 billion calculations a day across all 15,000 publicly traded U.S. stocks, plus crypto and ETFs. The system flagged Nvidia as a Buy back in 2011, before its nearly 30,000% run, and warned on banks ahead of the 2008 crisis. Three bonus reports now name stocks to buy, stocks to avoid, and crypto picks worth watching.November 6 at 1:00 AM | Weiss Ratings (Ad)Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingOctober 29, 2026 | globenewswire.comImmunocore Doses First Patient in Phase 1 Trial of Type 1 Diabetes TherapyOctober 15, 2026 | finance.yahoo.comImmunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetesOctober 15, 2026 | globenewswire.comSee More Immunocore Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email. Email Address About ImmunocoreImmunocore (NASDAQ:IMCR) Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells. The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype. Immunocore is also advancing additional investigational therapies targeting cancers and exploring applications of its TCR technology in infectious diseases. Immunocore was founded in the United Kingdom and is headquartered in Abingdon, England, with operations serving international pharmaceutical and healthcare markets. The company’s shares trade on the Nasdaq Global Select Market under the symbol IMCR. Bahija Jallal has served as Immunocore’s chief executive officer since 2019.View Immunocore ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to WatchQualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a CatchUber's Profit Drop: A Speed Bump or Structural Shift?Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What's Still Missing?Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Datadog's Post-Earnings Sell-Off: A Buying Opportunity in Plain Sight? Upcoming Earnings Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
